Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pro-urokinase for Extended-Window Posterior Circulation Stroke
Sponsor: The First Affiliated Hospital of Zhengzhou University
Summary
This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.
Official title: Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
586
Start Date
2026-06-01
Completion Date
2028-06-30
Last Updated
2026-06-01
Healthy Volunteers
No
Conditions
Interventions
rhPro-UK
rhPro-UK (5 mg/vial), to maximum of 35mg
placebo
Asprin (placebo)
Aspirin
Asprin (300mg)
Placebo
rhPro-UK(placebo)
Locations (1)
Department of Neurology, the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China